Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...

Creating cancer therapies based around natural killer cells could offer similar levels of efficacy to CAR-T therapies, but at around one hundredth of the cost. Researchers at MD Anderson Cancer ...

Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...

The main difference between these CAR-NK cells and the FDA-approved CAR-T cell products lies in the ease of manufacturing. Currently, 10-20% of patients who need CAR-T cell therapy can't access ...